Compare iShares MSCI Taiwan ETF (EWT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Zoetis Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.41, while Zoetis Inc trades at $73.9 (market cap $30.39B). The key difference: Zoetis Inc pays a 2.88% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWT | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $156.76 |
52-Week Low | $58.05 | $71.91 |
Market Cap | — | $30.39B |
Enterprise Value | — | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.19, up 3.92% with strong bullish momentum from moving averages. The ETF benefits from Taiwan's AI-driven semiconductor exposure, particularly through TSMC's 22.5% weighting. Recent news highlights continued capital flows into Taiwan's tech sector despite regional volatility, with MediaTek and ASE Technology announcing significant AI-related investments.
Outlook remains positive given Taiwan's leadership in semiconductor manufacturing and AI supply chain dominance. Key risks include geopolitical tensions with China and potential rotation away from AI-heavy markets. Institutional sentiment appears constructive with selective foreign inflows supporting the ETF's premium valuation.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
